Adjuvant Intermittent Chemoimmunotherapy for Primary Breast Cancer: A Prospective Study with Immunologic Follow-Up
- 1 January 1982
- book chapter
- Published by Springer Nature
- Vol. 80, 185-191
- https://doi.org/10.1007/978-3-642-81685-7_30
Abstract
In an interdisciplinary prospective study 50 patients surgically treated for breast cancer were treated with six monthly courses of aggressive adjuvant chemotherapy (adriamycin and cyclophosphamide) and were randomized to receive either immunotherapy with levamisole or no additional therapy. Probability of disease-free survival for the whole group is 54.9% at 42 months. There was no noticeable difference in disease-free survival for either pre- and postmenopausal women or for patients treated with or without levamisole. The addition of levamisole had no effect on the depression of in vitro immunologic functions during chemotherapy.Keywords
This publication has 4 references indexed in Scilit:
- Verhalten Iymphatischer Subpopulationen unter zytostatischer TherapiePublished by Springer Nature ,1978
- Combination Chemotherapy as an Adjuvant Treatment in Operable Breast CancerNew England Journal of Medicine, 1976
- LEVAMISOLE IN ADVANCED HUMAN BREAST CANCERThe Lancet, 1976
- L-Phenylalanine Mustard (L-PAM) in the Management of Primary Breast CancerNew England Journal of Medicine, 1975